J H Jacob - Concepedia

Concepedia

Author

J H Jacob

Centre François Baclesse

Also Known As

J H Jacob, J Jacob, J. H. Jacob, J. Jacob, J.-H. Jacob, J.H Jacob, J.H. Jacob, Jacob J., Jacques H. Jacob, Jacques Henry Jacob

31

Publications

1.3K

Citations

16

H-Index

20

Concepts

All Affiliations

Centre François Baclesse Centre Hospitalier Universitaire de Caen Normandie Centre François Baclesse Centre Eugène Marquis Centre Oscar Lambret

JH

About

J H Jacob is an author at Centre François Baclesse specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	771
2	Health Sciences	6	6	282
3	Gastroenterology	4	4	95
4	Pathology	4	4	460
5	Hepatology	1	1	32

J H Jacob

×

17

Publications

1.3K

Citations

16

H-Index

	Year	Citations
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer Harry Bleiberg, Thierry Conroy, B Paillot, European Journal of Cancer Esophageal CancerGastrointestinal OncologyMedicinePathologyPhase Ii Study	1997	347
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer Érick Gamelin, R. Delva, J H Jacob, Journal of Clinical Oncology	2008	330
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. Thierry Conroy, Pierre-Luc Etienne, Antoine Adenis, Journal of Clinical Oncology	1996	99
A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) Marc Ychou, Jean‐Luc Raoul, Jean‐Yves Douillard, Journal of Clinical Oncology Surgical OncologyAdjuvant TrialPathologySurgeryPharmacotherapy	2005	82
Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial Pierre Michel, Antoine Adenis, F. Di Fiore, British Journal of Cancer Weekly CisplatinSurgical OncologyEsophageal CancerSurgeryRadiation Medicine	2006	51
Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: Final results of a controlled clinical trial Alexandre Roussel, Harry Bleiberg, O. Dalesio, International Journal of Radiation OncologyBiologyPhysics Final ResultsEsophageal CancerRadiation TherapyControlled Clinical TrialMedicine	1989	49
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer Marc Ychou, Jean‐Luc Raoul, Françoise Desseigne, Cancer Chemotherapy and Pharmacology First-line TherapyOncologyGastrointestinal OncologyMedicineColorectal Cancer	2002	47
Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus Th. Wobbes, B. Barón, B Paillot, European Journal of Cancer Esophageal CancerRadiation TherapyMedicineSplit-course RadiotherapyOncology	2001	47
Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study Yassine Eid, Véronique Bouvier, Benjamin Menahem, Surgery Gastrointestinal OncologyHealth-related QualityMedicineGastroenterologyColorectal Cancer	2019	36
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer David Fallik, Marc Ychou, J H Jacob, Annals of Oncology Surgical OncologyOncologyHepatologyHealth SciencesGastrointestinal Oncology	2003	32

Page 1